Precision Wealth Strategies LLC Buys Shares of 14,063 Kiniksa Pharmaceuticals International, plc $KNSA

Precision Wealth Strategies LLC bought a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 14,063 shares of the company’s stock, valued at approximately $677,000.

Other institutional investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 11.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,356 shares of the company’s stock valued at $739,000 after acquiring an additional 1,584 shares during the last quarter. Bank of New York Mellon Corp grew its position in Kiniksa Pharmaceuticals International by 20.2% during the 1st quarter. Bank of New York Mellon Corp now owns 17,388 shares of the company’s stock worth $837,000 after acquiring an additional 2,917 shares during the last quarter. Hsbc Holdings PLC acquired a new position in Kiniksa Pharmaceuticals International in the 1st quarter worth about $248,000. Inspire Investing LLC acquired a new position in Kiniksa Pharmaceuticals International in the 1st quarter worth about $1,698,000. Finally, Cannon Global Investment Management LLC bought a new position in Kiniksa Pharmaceuticals International in the first quarter valued at about $530,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 58,424 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the completion of the transaction, the insider owned 65,623 shares in the company, valued at approximately $3,524,611.33. This trade represents a 47.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the firm’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total transaction of $656,259.90. Following the transaction, the director owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. The trade was a 51.08% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 628,427 shares of company stock valued at $32,833,228 over the last ninety days. 51.98% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on KNSA. Citigroup lifted their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Zacks Research raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, June 17th. Weiss Ratings lowered shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 23rd. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, June 29th. Finally, Jefferies Financial Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $65.14.

Kiniksa Pharmaceuticals International Stock Up 4.6%

Shares of NASDAQ:KNSA opened at $63.95 on Friday. The firm has a market cap of $4.92 billion, a P/E ratio of 71.06 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 12-month low of $26.27 and a 12-month high of $67.53. The business has a fifty day simple moving average of $56.42 and a 200 day simple moving average of $49.21.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. The firm had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The business’s revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.11 EPS. As a group, equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.25 EPS for the current year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.